10 mg · 20 mg
Tesamorelin
GHRH analog studied in GH/IGF-1 signaling and visceral fat, including trials in people with HIV and altered fat distribution.
For research use only
Retatrutide
Investigational peptide targeting GIP, GLP-1 and glucagon receptors. Studied in clinical trials on body weight and glycemic control.
- Pay by card (Stripe) or Zelle
- Ships within the U.S. with tracking
- Questions? Call or email us
Benefits under study
Clinical studies in adults with obesity or type 2 diabetes.
- Body weight reduction
- Blood glucose control
- Action on GLP-1, GIP and glucagon receptors
Research overview
Retatrutide (LY3437943) is an investigational triple agonist that acts on the GIP, GLP-1 and glucagon receptors. It is one of the most closely followed incretin-based compounds in current metabolic research.
Its research spans metabolic signaling, appetite regulation and energy balance. A phase 2 trial published in The New England Journal of Medicine evaluated retatrutide in adults with obesity, with change in body weight as the primary outcome, and ongoing studies examine glycemic control in type 2 diabetes.
Available in 10, 20, 30 and 50 mg vials, supplied for laboratory research.
Scientific references
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
N Engl J Med, 2023 · PMID 37366315
View on PubMed
